Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1977 Aug 17;12(1):7-13.
doi: 10.1007/BF00561399.

An investigation of "absolute plasma level effect relationships" and "absolute cardioselectivity" with respect to beta-adrenoceptor blockade

Clinical Trial

An investigation of "absolute plasma level effect relationships" and "absolute cardioselectivity" with respect to beta-adrenoceptor blockade

C R Kumana et al. Eur J Clin Pharmacol. .

Abstract

In a group of 6 healthy (but physically unfit) volunteers an investigation was made of whether there was a true plasma level effect relationship and absolute "cardioselectivity" with respect to beta-adrenoceptor blockade due to practolol. To this end three treatments were given orally, namely placebo, practolol 100 mg and practolol 400 mg. Cardiac beta-adrenoceptor blockade was assessed by measuring the inhibition of exercise heart rate and pulmonary beta-adrenoceptor blockade was assessed by measuring the reduction in exercise peak flow rate, up to 24 h after each dose. Plasma practolol levels were determined spectrophotometrically. From the results obtained there was no reason to doubt the existence of a valid relationship between cardiac beta-adrenoceptor blocking activity and the plasma concentration of practolol. It was also concluded that even in non-asthmatics, practolol does not possess absolute "cardioselectivity" since significant reductions in peak flow rate were discernible during vigorous exercise, particularly when the large dose had been given.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol Chemother. 1968 Jan;32(1):201-18 - PubMed
    1. Br Med J. 1969 Jul 19;3(5663):143-5 - PubMed
    1. Br Med J. 1970 May 30;2(5708):515-6 - PubMed
    1. Lancet. 1967 Jul 1;2(7505):12-5 - PubMed
    1. Lancet. 1972 Apr 15;1(7755):814-5 - PubMed

LinkOut - more resources